EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Glutamine Metabolism Transporter SLC25A22 Enhances CD8+ T‐Cell Function and Anti‐PD‐1 Therapy Efficacy in Cervical Squamous Cell Carcinoma: Integrated Metabolomics, Transcriptomics and T‐Cell‐Incorporated Tumor Organoid Studies

Tingting Ren, Junjun Qiu, Fanghua Chen, Qian Jiang, Qinqin Liu, Tong Wu, Hua Jiang, Keqin Hua iD

Advanced Science · 2025

DOI: 10.1002/advs.202502225 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Tingting Ren und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, 419 Fangxie Road, Shanghai, 200011, China. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Medical Innovation Research of Shanghai Science and Technology, Shanghai Hospital Development Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cervical squamous cell carcinoma(CSCC) represents formidable challenge in clinical oncology, exacerbated by poor prognosis and resistance to current treatments, including anti‐PD‐1 therapy, highlighting the urgent need for alternative therapeuties. Metabolic characteristics have emerged as potential drivers of treatment resistance and immune evasion. Herein, 1) based on metabolomic and transcriptomic analyses of 44 CSCC and 18 normal tissues, glutamine‐enriched and immunosuppressive microenvironment is identified in CSCC. 2) Integrative metabolomic and transcriptomic analyses revealed the glutamine metabolism transporter SLC25A22 as a key mediator in high glutamine metabolism, immune checkpoint activation and CD8+T‐cell cytotoxicity. 3) Immunohistochemistry(IHC), multiplex IHC, and flow cytometry validation with clinical CSCC samples revealed not only increased SLC25A22, PD‐1 expression and reduced CD8+T‐cell cytotoxicity in CSCC but also increased SLC25A22 expression in high PD‐L1 expressed CSCC patients, suggesting the potential of targeting SLC25A22 for enhancing CD8+T‐cell cytotoxicity and improving anti‐PD‐1 efficacy, especially in high PD‐L1 expressed patients. 4) Novelly, 3D‐CSCC organoids are constructed, replicating parental tumor features, and 3D‐T‐cell‐incorporated CSCC organoid models, replicating the interaction between tumor cells and CD8+T cells, for in vitro experiments. 5) Importantly, it is validated through in vitro 3D T‐cell‐incorporated CSCC organoid models and in vivo animal experiments that targeting the glutamine metabolism transporter SLC25A22, showed promise in enhancing CD8+T‐cell cytotoxicity and sensitizing anti‐PD‐1 therapy. These findings provided insights for future clinical trials exploring metabolic modulation to improve immunotherapy responses in CSCC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesCarcinoma, Squamous CellUterine Cervical NeoplasmsHumansFemaleMiceMetabolomicsAnimalsGlutamineOrganoidsProgrammed Cell Death 1 ReceptorTumor MicroenvironmentTranscriptomeCell Line, Tumor

Stichwörter der Autor:innen

Cervical squamous cell carcinomaanti‐PD‐1 therapyglutamine metabolismmetabolic profilingtranscriptional analysis

Substanzen

GlutamineProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, 419 Fangxie Road, Shanghai, 200011, China.
  • Shanghai Key Laboratory of Female Reproductive Endocrine-Related Diseases, 413 Zhaozhou Road, Shanghai, 200011, China.

ORCID-Profile: Keqin Hua

Förderung

  • National Natural Science Foundation of China
  • Medical Innovation Research of Shanghai Science and Technology
  • Shanghai Hospital Development Center
  • Science and Technology Innovation Plan Of Shanghai Science and Technology Commission
  • Key Technologies Research and Development Program
  • Shanghai Municipal Hospital Development Center

Zitieren

APA

Ren, T., Qiu, J., Chen, F., Jiang, Q., Liu, Q., Wu, T., Jiang, H., & Hua, K. (2025). Targeting Glutamine Metabolism Transporter SLC25A22 Enhances CD8+ T‐Cell Function and Anti‐PD‐1 Therapy Efficacy in Cervical Squamous Cell Carcinoma: Integrated Metabolomics, Transcriptomics and T‐Cell‐Incorporated Tumor Organoid Studies. Advanced Science. https://doi.org/10.1002/advs.202502225

Vancouver

Ren T, Qiu J, Chen F, Jiang Q, Liu Q, Wu T, et al. Targeting Glutamine Metabolism Transporter SLC25A22 Enhances CD8+ T‐Cell Function and Anti‐PD‐1 Therapy Efficacy in Cervical Squamous Cell Carcinoma: Integrated Metabolomics, Transcriptomics and T‐Cell‐Incorporated Tumor Organoid Studies. Advanced Science. 2025. doi:10.1002/advs.202502225

BibTeX
@article{Ren2025,
  author = {Ren, Tingting and Qiu, Junjun and Chen, Fanghua and Jiang, Qian and Liu, Qinqin and Wu, Tong and Jiang, Hua and Hua, Keqin},
  title = {Targeting Glutamine Metabolism Transporter SLC25A22 Enhances CD8+ T‐Cell Function and Anti‐PD‐1 Therapy Efficacy in Cervical Squamous Cell Carcinoma: Integrated Metabolomics, Transcriptomics and T‐Cell‐Incorporated Tumor Organoid Studies},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202502225}
}
Kostenlos starten →